Vageli Dimitra P, Kasle David, Doukas Sotirios G, Doukas Panagiotis G, Sasaki Clarence T
The Yale Larynx Laboratory, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Oncotarget. 2020 Sep 1;11(35):3303-3314. doi: 10.18632/oncotarget.27706.
Supraesophageal bile reflux at strongly acidic pH can cause hypopharyngeal squamous cell cancer, through activation of the oncogenic NF-κB-related pathway. We hypothesize that topical pre- or post-application of pharmacologic NF-κB inhibitor, BAY 11-7082 (0.25 μmol), on murine (C57BL/6J) HM (twice a day for 10 days) can effectively inhibit acidic bile (10 mmol/l; pH 3.0) induced oncogenic molecular events, similar to prior findings. We demonstrate that the administration of BAY 11-7082, either before or after acidic bile, eliminates NF-κB activation, prevents overexpression of and deregulations of , , linked to bile reflux-related hypopharyngeal cancer. Pre- but not post-application of NF-κB inhibitor, significantly blocks overexpression of and prostaglandin H synthases 2 (), and reverses phenotypes, supporting its early bile-induced pro-inflammatory effect. We thus provide novel evidence that topical administration of a pharmacological NF-κB inhibitor, either before or after acidic bile exposure can successfully prevent its oncogenic mRNA and miRNA phenotypes in HM, supporting the observation that co-administration of NF-κB inhibitor may not be essential in preventing early bile-related oncogenic events and encouraging a capacity for further translational exploration.
强酸性pH条件下的食管上胆汁反流可通过激活致癌性NF-κB相关途径导致下咽鳞状细胞癌。我们假设,在小鼠(C57BL/6J)下咽黏膜(HM)上局部预先或事后应用药理学NF-κB抑制剂BAY 11-7082(0.25 μmol,每天两次,共10天),可有效抑制酸性胆汁(10 mmol/l;pH 3.0)诱导的致癌分子事件,这与先前的研究结果相似。我们证明,在酸性胆汁之前或之后给予BAY 11-7082,可消除NF-κB激活,防止与胆汁反流相关的下咽癌相关的、、的过表达和失调。预先(而非事后)应用NF-κB抑制剂可显著阻断的过表达和前列腺素H合成酶2(),并逆转表型,支持其早期胆汁诱导的促炎作用。因此,我们提供了新的证据,表明在酸性胆汁暴露之前或之后局部应用药理学NF-κB抑制剂可成功预防其在HM中的致癌mRNA和miRNA表型,支持以下观察结果:联合应用NF-κB抑制剂可能不是预防早期胆汁相关致癌事件所必需的,并鼓励进一步进行转化探索的能力。